Bavarian Nordic Company Market Research Report
Company Overview
- Name: Bavarian Nordic
- Mission: A pioneering force in vaccines, expanding reach and impact through life-changing solutions.
- Founded: No information is available.
- Founders: No information is available.
- Key People:
- Paul Chaplin, President & CEO
- Henrik Juuel, Executive Vice President, Chief Financial Officer
- Jean-Christophe May, Executive Vice President, Chief Commercial Officer
- Russell Thirsk, Executive Vice President, Chief Operating Officer
- Luc Debruyne, Chair of the Board
- Headquarters: Denmark
- Number of Employees: More than 1,600
- Revenue: No information is available.
- Known For: Leading global provider of travel vaccines and a preferred partner with governments and international organizations for the delivery of vaccines improving public preparedness, such as mpox and smallpox vaccines.
Products
- Products Offered:
- Encepur®: Tick-borne Encephalitis Vaccine
- JYNNEOS® / IMVAMUNE® / IMVANEX®: Smallpox +/- Monkeypox Vaccine, Live, Non-replicating
- Rabipur® / RabAvert®: Rabies Vaccine for Human Use
- Vaxchora®: Cholera Vaccine, Live, Oral
- Vivotif®: Typhoid Vaccine Live Oral Ty21a
- High-Level Description: Bavarian Nordic specializes in live virus vaccine manufacturing with a comprehensive array of vaccines targeting various diseases, tailored for public health safety and preparedness.
- Key Features: No specific features available for each product.
Recent Developments
- Recent Developments:
- Bavarian Nordic reported preliminary 2024 financial results in line with upgraded guidance and provided guidance for 2025.
- The completion of the share buy-back program.
- Received a positive CHMP opinion for the Chikungunya vaccine for persons aged 12 and older.
- New Products Launched: No explicit information on newly launched products was available.
- New Features Added to Existing Products: No information is available.
- New Partnerships:
- Entered a license and manufacturing agreement for its Mpox vaccine with Serum Institute of India.
- Signed an agreement with UNICEF for 1 million Mpox vaccines.
- Awarded USD 63 million from the U.S. Government for production and supply of additional Smallpox/Mpox vaccines.
This report synthesizes the current state of Bavarian Nordic based on available data while identifying gaps where information is not provided.
